MX2024002465A - Formas solidas de inhibidores de bcl-2, metodo de preparacion y sus usos. - Google Patents
Formas solidas de inhibidores de bcl-2, metodo de preparacion y sus usos.Info
- Publication number
- MX2024002465A MX2024002465A MX2024002465A MX2024002465A MX2024002465A MX 2024002465 A MX2024002465 A MX 2024002465A MX 2024002465 A MX2024002465 A MX 2024002465A MX 2024002465 A MX2024002465 A MX 2024002465A MX 2024002465 A MX2024002465 A MX 2024002465A
- Authority
- MX
- Mexico
- Prior art keywords
- bcl
- inhibitors
- preparation
- solid forms
- solid form
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 4
- 239000012664 BCL-2-inhibitor Substances 0.000 title abstract 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 title abstract 2
- -1 (1H-pyrrolo [2, 3-b] pyridin-5-yl) oxy Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021115718 | 2021-08-31 | ||
| PCT/CN2022/116084 WO2023030363A1 (en) | 2021-08-31 | 2022-08-31 | Solid forms of bcl-2 inhibitors, method of preparation, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002465A true MX2024002465A (es) | 2024-04-29 |
Family
ID=85410866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002465A MX2024002465A (es) | 2021-08-31 | 2022-08-31 | Formas solidas de inhibidores de bcl-2, metodo de preparacion y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240317743A1 (https=) |
| EP (1) | EP4396180A4 (https=) |
| JP (1) | JP2024530315A (https=) |
| KR (1) | KR20240054327A (https=) |
| CN (1) | CN118215660A (https=) |
| AU (1) | AU2022336557A1 (https=) |
| CA (1) | CA3230314A1 (https=) |
| IL (1) | IL311106A (https=) |
| MX (1) | MX2024002465A (https=) |
| TW (1) | TW202328125A (https=) |
| WO (1) | WO2023030363A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296582A (en) | 2020-04-15 | 2022-11-01 | Beigene Ltd | bcl-2 inhibitor |
| WO2026002056A1 (en) | 2024-06-26 | 2026-01-02 | Beone Pharmaceutical (Suzhou) Co., Ltd. | A pharmaceutical formulation comprising solid dispersion of sonrotoclax and a process of preparation thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138588A2 (en) * | 2009-05-26 | 2010-12-02 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP2668180B1 (en) * | 2011-01-25 | 2018-08-01 | The Regents of The University of Michigan | Bcl-2/bcl-xl inhibitors for use in the treatment of cancer |
| SG11202009933WA (en) * | 2018-04-29 | 2020-11-27 | Beigene Ltd | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
-
2022
- 2022-08-31 EP EP22863498.6A patent/EP4396180A4/en active Pending
- 2022-08-31 JP JP2024513277A patent/JP2024530315A/ja active Pending
- 2022-08-31 CA CA3230314A patent/CA3230314A1/en active Pending
- 2022-08-31 AU AU2022336557A patent/AU2022336557A1/en active Pending
- 2022-08-31 WO PCT/CN2022/116084 patent/WO2023030363A1/en not_active Ceased
- 2022-08-31 MX MX2024002465A patent/MX2024002465A/es unknown
- 2022-08-31 CN CN202280058535.7A patent/CN118215660A/zh active Pending
- 2022-08-31 IL IL311106A patent/IL311106A/en unknown
- 2022-08-31 TW TW111132850A patent/TW202328125A/zh unknown
- 2022-08-31 KR KR1020247010341A patent/KR20240054327A/ko active Pending
-
2024
- 2024-02-27 US US18/589,022 patent/US20240317743A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024530315A (ja) | 2024-08-16 |
| WO2023030363A1 (en) | 2023-03-09 |
| CA3230314A1 (en) | 2023-03-09 |
| KR20240054327A (ko) | 2024-04-25 |
| CN118215660A (zh) | 2024-06-18 |
| AU2022336557A1 (en) | 2024-03-21 |
| EP4396180A4 (en) | 2025-07-09 |
| TW202328125A (zh) | 2023-07-16 |
| EP4396180A1 (en) | 2024-07-10 |
| US20240317743A1 (en) | 2024-09-26 |
| IL311106A (en) | 2024-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024002465A (es) | Formas solidas de inhibidores de bcl-2, metodo de preparacion y sus usos. | |
| FI3788042T3 (fi) | Bcl-2-inhibiittoreita | |
| PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
| MX2022016230A (es) | Clorhidrato de (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-nmetilm etanamina cristalino y formulaciones de las mismas. | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| CO2017008862A2 (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina | |
| BR112013012740A2 (pt) | sais e formas cristalinas de um agente que induz apoptose | |
| PE20160287A1 (es) | Inhibidores cristalinos de bromodominos | |
| PE20190437A1 (es) | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo | |
| AR111233A1 (es) | Inhibidores de tyk2, usos y métodos para la producción de los mismos | |
| EA201170537A1 (ru) | Ингибиторы вич-интегразы | |
| MX2009003985A (es) | Fenil-acetamidas utiles como inhibidores de cinasa de proteina. | |
| PH12017501699A1 (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors | |
| PH12023553203A1 (en) | Methods of treating b-cell malignancy using bcl-2 inhibitor | |
| GEP20186932B (en) | Pharmaceutical formulations of pan-raf kinase inhibitor, processes for their preparation, and methods of use | |
| MY207759A (en) | Pharmaceutical drug containing heterocyclidene acetamide derivative | |
| CL2020003015A1 (es) | Conversión a escala preparativa de goniautoxinas en neosaxitoxina | |
| AR074685A1 (es) | Derivados de 6-cicloamino -2,3-di- piridinil-imidazo (1,2-beta) -piridazina, su preparacion, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la fosforilacion de las caseinas quinasa 1 epsilon y delta. | |
| MX2025000776A (es) | Metodos de tratamiento del mieloma multiple con un inhibidor de bcl-2 | |
| WO2011025683A8 (en) | Hiv integrase inhibitors | |
| CL2017002180A1 (es) | Formas cristalinas de un compuesto de pirrolopiridina | |
| BR112018075823A2 (pt) | sais farmacêuticos de n-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida e suas formas cristalinas | |
| EA201270475A1 (ru) | Комбинация | |
| CL2019003848A1 (es) | Nueva sal de n-(2,6-dietilfenil)-8-({4-[4-(dimetilamino) piperidin-1-il]-2-metoxifenil}amino)-1-metil-4,5-dihidro-1h pirazolo[4,3-h]quinazolina-3-carboxamida, su preparación, y las formulaciones que la contienen | |
| MX2025007582A (es) | Un intermedio protegido de cetal para sonrotoclax y su metodo de preparacion |